# Novel Use of Restasis and PROSE Devices

> **NCT04735510** · PHASE3 · WITHDRAWN · sponsor: **Boston Sight**

## Conditions studied

- Ocular Surface Disease

## Interventions

- **DRUG:** cyclosporine ophthalmic emulsion 0.05%

## Key facts

- **NCT ID:** NCT04735510
- **Lead sponsor:** Boston Sight
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-05
- **Primary completion:** 2021-09
- **Final completion:** 2021-09
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** study redesigned
- **Last updated:** 2023-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04735510

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04735510, "Novel Use of Restasis and PROSE Devices". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04735510. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*